Peak Bio Inc (PKBO) Return on Equity ROE from the third quarter 2024 to third quarter 2023 and annually, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Peak Bio Inc   (NONE: PKBO)

Peak Bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Peak Bio Inc in the third quarter 2024?
Due to the lack of equity, it was not possible to calculate Peak Bio Inc 's return on equity (ROE) in its third quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change 317.44 % - - - -
Net Income (TTM) in Millions -3 -5 -8 -13 1
Return On Equity (TTM) - - - - -
PKBO's Total Ranking # # # # #
Equity (TTM) in Millions -21 -23 -21 -18 -18
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to PKBO Management Effectiveness >> PKBO's 5 Years Annual ROE >> Compare PKBO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





PKBO Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021

Total Equity in Millions -18 -8 -2 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -13 -13 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to PKBO Management Effectiveness >> PKBO's 5 Years Annual ROE >> Compare PKBO ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PKBO's' Return on Equity at Yahoo Finance
PKBO's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PKBO's Competitors
Subscribers only: Roe for Peak Bio Inc 's Suppliers
Subscribers only: Return On Equity for PKBO's Customers




Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector ROE
Lantheus Holdings Inc   43.11 %
Puma Biotechnology Inc   41.50 %
Pharmacyte Biotech Inc   40.98 %
Collegium Pharmaceutical Inc   40.81 %
Entrada Therapeutics Inc   38.93 %
Adma Biologics Inc   38.43 %
Exagen Inc   36.80 %
Kewaunee Scientific Corporation  35.42 %
Protagonist Therapeutics inc   34.68 %
Dexcom Inc   31.20 %
Merck and Co Inc   29.26 %
Prestige Consumer Healthcare Inc   29.04 %
Hims and Hers Health Inc   27.17 %
Engene Therapeutics Inc   26.95 %
Msa Safety Inc  26.74 %
Alkermes Plc   26.49 %
Acadia Pharmaceuticals Inc   25.83 %
Catalyst Pharmaceuticals Inc   25.74 %
Chemed Corporation  25.49 %
Corcept Therapeutics Inc  24.54 %
Sbc Medical Group Holdings Incorporated  24.03 %
Iradimed Corporation  23.98 %
Resmed Inc   23.65 %
Harmony Biosciences Holdings inc   23.16 %
Agilent Technologies inc   22.98 %
Amphastar Pharmaceuticals Inc   22.92 %
Encompass Health Corporation  22.58 %
Ge Healthcare Technologies Inc   22.51 %
Iqvia Holdings Inc   21.50 %
Kiora Pharmaceuticals Inc   21.31 %

Date modified: 2026-09-26T07:40:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.